BIAO YANG^1,3,#,*, MINLAN YUAN^2,#, TING YANG^1,#, ZHENGYIN LIAO¹, HAO WU^3,*

Oncology Research, Vol.30, No.1, pp. 23-33, 2022, DOI:10.32604/or.2022.026044 - 06 December 2022

Abstract Treatment of hepatocellular carcinoma (HCC) in the caudate lobe is technically challenging. This retrospective study was designed to evaluate the clinical outcome of both superselective transcatheter arterial chemoembolization (TACE) and liver resection (LR) for HCC occurring exclusively in the caudate lobe. From January 2008 to September 2021, a total of 129 patients were diagnosed with HCC of the caudate lobe. The Cox proportional hazard model was used to analyze the potential clinical factors and established prognostic nomograms with interval validation. Of the total number of patients, 78 received TACE and 51 received LR. The overall… More >

Xin Chang^1,2,#,*, Jin Wang^2,#, Caifang Ni¹

Oncologie, Vol.23, No.1, pp. 119-130, 2021, DOI:10.32604/oncologie.2021.014152 - 30 March 2021

Abstract Objective: This research was designed to observe the value of miR-1271 and GPC3 in evaluating the prognosis of liver cancer (LC) patients after liver transarterial chemoembolization (TACE). Methods: A total of 80 patients diagnosed as LC in our hospital from January 2018 to April 2019 were included in the LC group (LCG), and then assigned into a survival group (SG) and a death group (DG) based on prognosis. Seventy healthy subjects undergoing physical examination simultaneously were included in the normal group (NG). miR-1271 and GPC3 in serum of two groups of subjects were tested via qRT-PCR.… More >

Junhui Sun^*1, Guanhui Zhou^*1, Xiaoxi Xie^†, Wenjiang Gu^‡, Jing Huang^§, Dedong Zhu^¶, Wenhao Hu^#, Qinming Hou^**, Changsheng Shi^††, Tiefeng Li^‡‡ , Xin Zhang^§§, Wenbin Ji^¶¶, Shihong Ying^§§, Zhiyi Peng^§§, Jian Zhou^##, Zhihai Yu^***, Jiansong Ji^†††, Haijun Du^‡‡‡, Xiaohua Guo^§§§, Jian Fang^¶¶¶, Jun Han^###, Huanhai Xu^****, Zhichao Sun^††††, Wenqiang Yu^‡‡‡‡, Guoliang Shao^§§§§, Xia Wu^¶¶¶¶ ,Hongjie Hu^¶¶¶¶ , Ling Li^#, Jiaping Zheng^§§§§, Jun Luo^§§§§, Yutang Chen^§§§§, Guohong Cao^####, Tingyang Hu^‡‡‡‡

Oncology Research, Vol.28, No.1, pp. 75-94, 2020, DOI:10.3727/096504019X15662966719585

Abstract The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response (CR), partial response (PR), and objective response… More >

Zhiyi Peng^*1, Guohong Cao^†1, Qinming Hou^‡, Ling Li^§, Shihong Ying^*, Junhui Sun^¶, Guanhui Zhou^¶, Jian Zhou^#, Xin Zhang^*, Wenbin Ji^**, Zhihai Yu^††, Tiefeng Li^‡‡, Dedong Zhu^§, Wenhao Hu^§§, Jiansong Ji^¶¶, Haijun Du^##, Changsheng Shi^***, Xiaohua Guo^†††, Jian Fang^‡‡‡, Jun Han^§§§, Wenjiang Gu^¶¶¶, Xiaoxi Xie^###, Zhichao Sun^****, Huanhai Xu^††††, Xia Wu^‡‡‡‡, Tingyang Hu^§§§§, Jing Huang^¶¶¶¶, Hongjie Hu^‡‡‡‡, Jiaping Zheng^####, Jun Luo^####, Yutang Chen^####, Wenqiang Yu^§§§§, Guoliang Shao^####

Oncology Research, Vol.28, No.3, pp. 249-271, 2020, DOI:10.3727/096504019X15766663541105

Abstract This study aimed to investigate the efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treating Chinese patients with liver cancer. A total of 367 liver cancer patients from 24 medical centers were consecutively enrolled in this multiple-center, prospective cohort study, including 275 hepatocellular carcinoma (HCC) cases, 37 intrahepatic cholangiocarcinoma (ICC) cases, and 55 secondary liver cancer cases. All the patients received CalliSpheres^® DEB-TACE treatment. Treatment response, overall survival (OS), change of liver function, and adverse events (AEs) were assessed. DEB-TACE treatment achieved 19.9% complete response (CR) and 79.6% objective response rate (ORR),… More >

Ping Wen^*, Sheng-Duo Chen^*, Jia-Rui Wang^†, Ying-He Zeng^*

Oncology Research, Vol.27, No.5, pp. 583-592, 2019, DOI:10.3727/096504018X15368325811545

Abstract This study evaluated the difference in treatment response and survival profiles between drug-eluting bead transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (cTACE) treatments in Chinese hepatocellular carcinoma (HCC) patients. A total of 120 HCC patients were consecutively enrolled in this prospective cohort study, which showed that DEB-TACE achieved higher complete response (CR) (30.8%) compared with cTACE (7.4%) with no difference in overall response rate (ORR) for patients treated with DEB-TACE and cTACE (80.8% vs. 73.5%). In addition, DEB-TACE was associated with a lower rate of progressive disease (PD) compared with cTACE (1.9% vs. 11.8%). With… More >

Yaohong Liu, Wensou Huang, Mingji He, Hui Lian, Yongjian Guo, Jingjun Huang, Jingwen Zhou, Kangshun Zhu

Oncology Research, Vol.27, No.5, pp. 565-573, 2019, DOI:10.3727/096504018X15313896322888

Abstract This study aimed to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Barcelona Clinic Liver Cancer (BCLC) stage C liver cancer patients. In 39 patients with BCLC stage C liver cancer, after the first cycle of DEB-TACE, 2 (5.1%) and 24 (61.5%) patients achieved complete response (CR) and partial response (PR) to give an overall objective response rate (ORR) of 66.7%. With respect to the second cycle of therapy, the ORR was higher in patients receiving DEB-TACE compared with those receiving cTACE (57.1% vs. 11.1%). After the first cycle of… More >